Related Experiment Video
Updated: May 7, 2026
10:58
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
17.0K
Utilizing AfDesign for Developing a Small Molecule Inhibitor of PICK- 1-PDZ.
Emily Hendrix1, Xinyu Xia1, Amy O Stevens1
1Department of Chemistry and Chemical Biology, The University of New Mexico, Albuquerque, New Mexico 87131, USA.
Current Protein & Peptide Science
|August 22, 2024
Summary
AfDesign, a new computational tool, can generate effective ligands targeting the PICK1 PDZ domain. This protein-protein interaction inhibitor design shows promise for neurological disorder drug discovery.
Area of Science:
- Computational biology
- Drug discovery
- Protein-protein interactions
Background:
- The PICK1 PDZ domain is a potential therapeutic target for neurological disorders.
- Existing experimental inhibitors like TAT-C5 and mPD5 show high binding affinity.
- There is a need for advanced computational methods to design novel protein-targeting ligands.
Purpose of the Study:
- To evaluate the efficacy of AfDesign, an AlphaFold-based program, in generating ligands for the PICK1 PDZ domain.
- To explore the impact of ligand length and computational cycles on ligand generation.
Main Methods:
- Utilized AfDesign (part of ColabDesign) to design ligands targeting the PICK1 PDZ domain.
- Investigated the role of sequence length and recycle count in AfDesign's ligand generation process.
Main Results:
- AfDesign successfully generated ligands targeting the PICK1 PDZ domain.
- A ligand sequence length of 5 yielded the most comparable results to known inhibitors.
- Designed ligands exhibited significantly lower binding energy than manually designed sequences.
Conclusions:
- AfDesign demonstrates potential as a powerful computational tool for ligand discovery.
- The program can facilitate the exploration of ligand space for targeting PDZ domains.
- This approach aids in the development of novel therapeutics for neurological conditions.
